LONDON – Just four months after setting regenerative medicine alive with the first big ticket deal in the field, Mesoblast Ltd. has been forced to reassure shareholders it is immune to any change of strategic direction arising from Valeant Pharmaceuticals International Inc.'s unsolicited offer for Mesoblast's partner, Cephalon Inc. (BioWorld International) Read More
